Integrato FINAL MEETING and WORKSHOP

26th -27th May 2022 - University of Sheffield - UK

Meeting venue:

Inox - Level 5, Students' Union Building Durham Road, Sheffield S10 2TG, UK http://inoxdine.co.uk/

SCIENTIFIC MEETING - 26th May 2022

(Only INTEGRATA members, fellows and AB)

15 min presentation each fellow + 5 min discussion

09.00-09.10 Welcome and Introduction Patrick Herr- University of Sheffield, UK Alessio Nencioni - INTEGRATA coordinator - Università degli Studi di Genova, Italy

SESSION I: Development and/or *in vitro* testing of new NAMPT and NAPRT inhibitors

- **09.10-09.30 Biochemical and cellular effects of NAPRT inhibitors in PDAC cells** Mochammad Ichsan - Universität Bonn, Germany
- 09.30-09.50 Biochemical and cellular effects of NAMPT inhibitors in haematological cancer cells

Paulina Binieka - Centre Hospitalier Universitaire Vaudois, Switzerland

- **09.50-10.10 New FK866 analogues, NAMPT inhibitors** Simone Fratta - Universidad de Sevilla, Spain
- **10.10-10.30** New compounds circumventing resistance to NAMPT inhibition Ágata Carreira - Università degli Studi di Trento, Italy
- **10.30-10.50** New NAMPT inhibitors with imino-C-glycoside structures Irene Conforti - Université de Montpellier, France
- 10.50-11.05 Coffee break
- 11.05-11.25 New NAPRT inhibitors

Jorge Sus Franco - Innovamol Consulting, Italy

11.25-11.45 NAD precursor-depleted diets as a means to sensitize cancer cells to NAMPT inhibitors and chemotherapeutics Moustafa Ghanem - Università degli Studi di Genova, Italy

SESSION II: Development and *in vitro* testing of ADCs of NAMPT inhibitors

11.45-12.05 ADCs of NAMPT inhibitors with anticancer activity

Pablo Ruedas-Batuecas - Heidelberg Pharma Research GmbH, Germany

SESSION III: Development and *in vitro* testing of anti-eNAMPT and of anti-eNAPRT neutralizing Abs

12.05-12.25 Neutralizing anti-eNAMPT Abs

Elise Semerena, Novimmune - Light Chain Bioscience, Switzerland

12.25-14.00 Lunch



Integrato FINAL MEETING and WORKSHOP

26th -27th May 2022 - University of Sheffield - UK

SESSION IV: Development and *in vitro* testing of SIRT6, TRPM2, NUDT22 and CD73 inhibitors

14.00-14.20 New SIRT6 inhibitors

 Elena Abbotto - Università degli Studi di Genova, Italy

14.20-14.40 New NUDT22 inhibitors

 Melanie Walter - University of Sheffield, United Kingdom

14.40-15.00 New CD73 inhibitors

 Benjamin Gyau - Università degli Studi di Torino, Italy

15.00-15.20 New TRPM2 inhibitors

Swati Balasheb Ohol - Universitätsklinikum Hamburg-Eppendorf, Germany

SESSION V: Fingerprinting/pre-formulation, formulation, PK and biodistribution studies of NAD-lowering compounds and inhibitors of NAD/nucleotide signalling

15.20-15.40 In vivo metastasis and angiogenesis imaging as a reading frame for NAMPT inhibitor activity


Burak Kizil - Université de Genève, Switzerland

15.40-16.00 Coffee break

MANAGEMENT MEETING

- 16.00-17.00 Progress of the project
 - Potential issues in project activities, actions for completing the programme
 - Possible project extension
 - Next deadlines of the project, final reporting
 - General discussion
- **20.00** *Dinner* (including invited speakers for the next day)







Integrate FINAL MEETING and WORKSHOP


26th -27th May 2022 - University of Sheffield - UK

WORKSHOP "Metabolic targets for cancer therapy" - 27th May 2022 (Symposium open also to external participants)

- **09.00-09.30 Development of ectonucleotidase inhibitors as tools and drugs** Christa Muller - Universität Bonn, Germany
- **09.30-10.00 Is PARG a better target than PARP for cancer therapy ?** Helen Bryant - University of Sheffield, United Kingdom
- 10.00-10.30 Plasticity of Serine Metabolism in context of Cancer Cell Invasion and Metastasis

Johannes Meiser - Luxembourg Institute of Health, Luxembourg

- 10.30-10.45 Coffee break
- **10.45-11.15 Ex Vivo DEtermined caNcer Therapy (EVIDENT)** Greg Wells - University of Sheffield, United Kingdom
- **11.15-11.45 TBA** Antonella Spinazzola - University College London, UK
- **11.45-12.15** Linking metabolism to epigenetics and cancer, one gene at a time Raul Mostovlasky - Massachusetts General Hospital, USA (*on line*)
- 12.15-14.00 Lunch
- 14.00 Departures



Organization and Graphic project by

